Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

Phase 3Etripamil Nasal SprayPositive

AI Analysis

Summary

Milestone Pharmaceuticals enrolled the first Canadian study participant in the ReVeRA-301 Phase 3 pivotal trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate, with Montreal Heart Institute joining the multinational study.

Clinical Trial Data

Phase

Phase 3

Importance:5/10

Sentiment:

0.50

Phase_3_TrialEtripamilAFibCanadaPatient_Enrollment

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 24, 2026 12:00 PM

Read Original